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Abstract 
Liver transplantation (LT) is the only avail-
able  live-saving  procedure  for  children  with
irreversible  liver  failure.  This  paper  reports
our experience from the follow-up of 16 Greek
children  with  end-stage  liver  failure  who
underwent a LT. Over a period of 15 years, 16
pediatric  liver  recipients  received  follow  up
after being subjected to OLT (orthotopic liver
transplantation) due to end-stage liver failure.
Nine children initially presented with extra-
hepatic biliary atresia, 2 with acute liver fail-
ure  after  toxic  mushroom  ingestion,  2  with
intrahepatic cholestasis, 2 with metabolic dis-
eases and one with hepatoblastoma. Ten chil-
dren received a liver transplant in the Organ
Transplantation Unit of Aristotle University of
Thessaloniki and the rest in other transplant
centers. Three transplants came from a living-
related donor and 13 from a deceased donor.
Six  children  underwent  immunosuppressive
treatment  with  cyclo  sporine,  mycophenolate
mofetil  and  corticosteroids,  and  7  with
tacrolimus, mycophenolate mofetil and corti-
costeroids. Three out of 16 children died with-
in the first month after the transplantation due
to  post-transplant  complications.  Three  chil-
dren presented with acute rejection and one
with chronic organ rejection which was suc-
cessfully  managed.  Five  children  presented
with  cytomegalovirus  infection,  5  with
Epstein-Barr  virus,  2  with  HSV1,2,  2  with
ParvoB19  virus,  2  with  varicella-zoster  virus
and one with C. Albicans infection. One child
presented with upper gastrointestinal hemor-
rhage and one with small biliary paucity. A sat-
isfying outcome was achieved in most cases,
with good graft function, except for the patient
with  small  biliary  paucity  who  required  re-
transplantation. 
The long-term clinical course of liver trans-
planted children is good under the condition
that they are attended in specialized centers.
Introduction
The  first  liver  transplant  (LT)  was  per-
formed in 1963 at the University of Colorado by
Starzl et al.
1in a 3-year old child with extrahep-
atic biliary atresia. The patient died during the
procedure due to hemorrhage. Four years later
the same team performed the first successful
liver transplant in an 18-month old infant with
hepatoblastoma who survived for 400 days.
2 In
the same decade in Europe there was a high
incidence  of  mortality  after  liver  transplant
that reached 60-70%.
3,4 Advances in immuno-
suppressive  therapy  and  surgical  techniques
increased survival rates, which in some cen-
ters were over 90% the first year after trans-
plantation in chronic liver failure and 70% in
acute liver failure. Today, ten and 15-year long-
term  survival  reaches  80%.
5-8 Reduced-size,
split liver and living related liver transplant has
markedly extended the possibility of transplan-
tion, especially in infants under the age of one
year and weighing less than 10 kg.
9-11
In this country, the first LT was performed in
1992  in  the  Organ  Transplanta  tion  Unit  of
Aristotle  University  of  Thessaloniki  in  a  7-
month old boy with extrahepatic biliary atresia.
He received a cadaveric transplant by using the
reduced-size technique. The patient is still alive
with a normal psycho-somatic development and
no complications. The objective of this study is
to report post-operative details of 16 pediatric
patients after a liver transplant who received
follow  up  in  the  Paediatric  Gastroente  rology
Department of our hospital.
Materials and Methods
From May 1992 to June 2007, 16 pediatric
liver recipients received follow up after being
subjected to OLT (Orthotopic Liver Transplant  -
ation)  due  to  end-stage  liver  failure.
Anticoagulation was with acetylosalycylic acid
at 50 mg once daily. Six patients were started
on cyclosporine 2-6 mg/kgr/day to achieve tar-
get levels of 200-400 ng/mL. Seven were start-
ed on tacrolimus 0.3 mg/kgr BW/day to achieve
target  levels  of  5-15  ng/mL.  All  patients
received  immunosuppression  with  pred-
nisolone  which  was  maintained  during  the
first post-transplant year in order to reduce the
risk of side effects. Immunosuppressive thera-
py was given with mycophenolate mofetil at a
dose of 100 mg/m
2 SA twice daily. Table 1 rep-
resents  a  protocol  on  immunosuppression
used in our Department.
ATG dosing for rejection was of 10 mg/kg/day,
4  times  daily.  Methylprednisolone  was  at  a
dose ranging from 100-200 mg/day IV.
All the patients have been subjected to a reg-
ular control for viral and parasitic infections
due to immunosuppression (Table 2).
Demographics and the cause of liver failure
in the 16 patients are reported in Table 3. Nine
patients had biliary atresia, 2 acute liver fail-
ure  after  toxic  mushroom  ingestion,  one
Alagille  syndrome,  one  non-syndromic  intra-
hepatic  biliary  paucity,  one  Wilson  disease,
one  primary  hyperoxaluria  and  one  hepato-
blastoma. Figure 1 shows the causes (%) that
led to LT in our patients. Ten children under-
went LT in the Organ Transplantation Unit of
Aristotle  University  and  6  in  other  medical
centers.  
Three out of 9 children who suffered from
biliary  atresia  underwent  a  Kasai  operation
prior  to  transplantation.  One  of  them  had
Kasai type I at the age of one month while the
second and third underwent Kasai type II at
the second and fourth month of age, respec-
tively.  The  evaluation  for  liver  insufficiency
was  based  on  the  Child-Pugh  criteria.
According to the Child-Pugh scores, one child
was classified as grade B and the remaining 8
as grade C. In 7 cases the donor was a child,
while in another 6 cases the graft was derived
from an adult. In 4 out of these 6 cases the split
liver technique was used. In each of these 4
cases the right lobe of the liver was allocated to
an adult recipient, while the parts II and III of
the grafts were allocated to children. In the
other 2 cases, the parts II and III of the liver
were separated by using the reduced-size tech-
nique, which means that the remaining part of
the graft cannot be used.
All patients received an immunosuppressive
induction  with  prednisolone.  Maintenance
immunosuppression in 13 patients consisted
of  mycophenolate  mofetil  (MMF)  and  a  cal-
cineurin  inhibitor  (cyclosporine  n=6,  tacro  -
limus n=7). Prednisolone in every case was
maintained up to one year post-transplant in
order to reduce the risk of side effects. The
other  3  patients  died  immediately  after  the
surgical procedure. They had received a regi-
men  of  cyclosporine  (n=2)  and  tacrolimus
(n=1) over a few days.
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Results
Three children died within the first month
due to post-transplant complications: hepatic
artery thrombosis n=1, portal vein thrombosis
n=1, hemorrhage n=1. The first patient was an
11-year old girl who suffered from hepatoblas-
toma  and  received  graft  from  a  cadaveric
donor. The graft loss was due to hepatic artery
thrombosis.  The  second  patient  was  a  22-
month old boy who suffered from extrahepatic
biliary atresia and also received a graft from a
cadaveric donor. The graft loss was due to por-
tal vein thrombosis. The third patient was a 4-
year old girl with primary hyperoxaluria who
died  on  the  30th  day  post-transplant  due  to
rupture  of  an  arterial  anastomosis  pseudoa-
neurysm. After a median period of 35 months
follow  up  (range  23-180),  13  out  of  the  16
transplanted children are still alive (Figure 2).
Four children followed in our Department
had at least one episode of chronic graft rejec-
tion. Two of them have been managed success-
fully with cortisone pulses, while anti-thymo-
cyte globulin (ATG) was necessary in 2 other
cases. In one of these cases the recipient did
not  have  the  same  but  an  ABO-compatible
blood group. The patient presented with chron-
ic  graft  rejection  which  was  managed  by
switching  the  immunosuppressive  regimen
from cyclosporine to tacrolimus.
Overall, a modified immunosuppressive reg-
imen  was  necessary  in  3  cases.  Another
patient  who  received  cyclosporine  presented
with hypertension and increased serum and
urea creatinine levels. Cyclosporine was dis-
continued  and  the  patient  was  placed  on
tacrolimus. A week later the patient had nor-
mal arterial pressure as well as normal urea
and creatinine levels. A patient who was on
tacrolimus presented with abdominal pain and
increased serum amylase which resolved after
the patient was switched to cyclosporine.
Immunosuppressive complications included
upper  gastrointestinal  hemorrhage  in  one
patient  and  hyperuricemia  in  another.  The
gastrointestinal bleeding was attributed to cor-
ticosteroids as no other cause was recognized
after  a  careful  investigation  which  included
endoscopy. The other patient who presented
with hyperuricemia has been on calcineurin
inhibitors for the last 14 years. Management
was with a proper dietary intervention and by
changing the immunosuppressive agent. The
long-term follow up regarding the psychosocial
development  of  these  transplanted  children
revealed normal growth parameters in terms of
weight gain, length and head circumference in
all the children, but mild neurodevelopmental
disorders in 3 of them with subnormal intellec-
tual functioning.
Viral  infections  were  assessed  with  poly-
merase  chain  reaction  (PCR)  and  revealed
Article
Table 1. Immunosuppressive agents used in transplanted patients.
Drug Dose Level
Cyclosporine 10-15 mg/kg for 1-2 weeks, 200-400 ng/mL
then 2-6 mg/kg in two daily doses 
(according to serum levels)
Mycophenolate mofetil 100 mg/m
2 SA x 2 daily
Tacrolimus (FK 506) 0.3 mg/kg/day twice daily, 5-15 ng/mL
0.05 mg/kg/day IV 
Table 2. Follow-up schedules for infections after pediatric liver transplant.
Exams 1-3 4-6 7-18 18-24 >24
months months monthsmonths months
CMV pp65,CMV DNA Week 1,2,3,4,5,6,8,12,and 16 If clinical suspicion of CMV infection
EBV DNA(quantitative  Week 1,2,3,4,5,6,8,12,and 16 Every other week
PCR on whole blood)
Serology: Hbs Ag, HbsAb, Every 6 months
HbcAb, HbeAb, HbeAg,
HCV RNA, HAV Abs (IgG,IgM), 
HSV(IgG,IgM),VZV(IgG,IgM), 
Toxoplasma(IgG,IgM)
Table 3. Demographics, causes of liver failure and mean time of follow up in 16 children
at the Hippokration University Hospital of Thessaloniki.
Age
Mean 4.7±2.3 years
Median 3.5 years (6 months-13 years)
<1 year 3
1-7 years 8
7-13 years
Gender
Male 8
Female 8
Causes
Extrahepatic biliary atresia 9
Toxic mushroom ingestion
Intrahepatic cholestasis 2
Metabolic diseases 2
Liver cancer 1 
Mean time of follow up 3.7 years
Figure 1. Causes (%) of liver failure in our cases.[page 46] [Pediatric Reports 2010; 2:e14]
cytomegalovirus  in  5  patients,  Epstein-Barr
virus in 5 patients and ParvoB19 infection in 2
patients. Two children presented with varicel-
la-zoster viral infection, 2 with HSV
1,2 and one
with C. albicans. Infection management was
with acyclovir, gancyclovir, amphotericin B and
by cutting down the immunosuppression. One
patient  with  ParvoB19  infection  presented
with jaundice due to small biliary paucity. He
progressed  to  hepatic  failure  requiring  re-
transplantation.  
Discussion
The survival rate of the pediatric liver recipi-
ents followed in our department so far has been
over 80% as 13 out 16 children are still alive.
The  recognized  post-transplant  complications
were  hepatic  artery  thrombosis  (n=1),  portal
vein thrombosis (n=1) and rupture of an arteri-
al  anastomosis  (n=1).  Concerning  survival
after  transplantation,  an  optimum  nutritional
status has been shown to improve the survival
rate and it was related to fewer infections and a
reduction in surgical complications.
Cholestatic liver diseases lead to fat malab-
sorption resulting in a deficiency of calories as
well  as  fat  soluble  vitamins.
12 The  patients
have greatly benefited from caloric and vita-
min  supplementation,  special  milk  formulas
with  medium  chain  triglycerides,  tube  feed-
ings or parenteral feedings as indicated. Four
of the patients with biliary atresia had a very
low  weight  at  presentation.  Their  weight
increased  with  proper  nutritional  support  to
20-30% before the transplantation leading to a
successful outcome.
Viral infections due to immunosuppression
were the second most common post-transplant
complication.  Patients  were  investigated  for
viral infections by means of PCR. The viruses
most commonly implicated were cytomegalo  -
virus, Epstein-Barr virus and Parvo B19 virus.
Herpes Simplex virus type 1 and 2, Coxsackie
virus and the mold C. albicans were less com-
mon causes of infection.
Children’s morbidity rate after transplanta-
tion is also affected by complications due to
immunosuppression. Such complications are
nephrotoxicity  due  to  calcineurin  inhibitors
(cyclosporine,  tacrolimus),  neurotoxicity,
osteoporosis  and  cardiovascular  diseases.
13-15
A very important factor that has been taken
into account in the choice of immunosuppres-
sive agent is that the patient’s renal function
should remain intact. The newer immunosup-
pressive drugs, such as mycophenolate mofetil
and sirolimus do not affect renal function. This
means that it is possible to achieve immuno-
suppression by using calcineurin inhibitors at
a lower dose to avoid their side effects.
16-18 Only
one of the patients who received cyclosporine
presented with renal insufficiency, increased
urea  levels  and  arterial  hypertension.  The
patient was initially managed by reducing the
dose of cyclosporine and concomitantly by plac-
ing the patient on tacrolimus.
Mental and cognitive disorders are common
in children after liver transplant. These may be
attributed  to  hepatic  encephalopathy  as  a
result of fulminant or chronic liver failure prior
to  transplantation.  Prolonged  hospitalization
and immunosuppressive regimens used after
transplantation,  particularly  corticosteroids,
have  also  been  implicated  for  mental  disor-
ders. Cognitive disorders were present in 2 of
the children who were transplanted due to ful-
minant liver failure after mushroom ingestion.
Minor learning disabilities were also present
in the child who was transplanted for Alagille
syndrome  and  was  mainly  attributed  to  pro-
longed hospitalization. Assessment was with
the  WISC  III  intelligence  test  (Weschler
Intelligence Scale For Children) which illus-
trated a mild mental retardation.The growth
parameters, such as the weight and length per-
centiles  and  the  head  circumference  per-
centile in relation to age and sex were within
the normal range in all the patients according
to Greek  growth scales. 
The number of candidates requiring a liver
transplant continuously increases as the indica-
tions  for  performing  transplantation  have
expanded. Allocating the available liver grafts to
the candidates has always been a major issue.
Patient evaluation to determine the priority for
transplantation is currently based on the stage
of the liver insufficiency according to the Child-
Turcotte-Pugh  score  and  also  by  taking  into
account the co-existing complications of the pri-
mary liver disease, such as ascites, hepatocellu-
lar carcinoma and variceal bleeding.
9,20
Compared to adults, pediatric patients who
have undergone LT are less likely to experi-
ence  a  relapse  of  the  primary  liver  disease.
This observation has been confirmed by the
higher survival proportion of the grafts in the
pediatric patients compared to adults.
ABO type seems to be a significant factor in
rejection. It is generally agreed that the bal-
ance  between  the  expression  of  ABO  blood
group  antigens  and  the  recipient’s  natural
antibodies has a marked effect on liver graft
survival rates. A comparison of liver graft sur-
vival rates in ABO-identical and ABO-compati-
ble but not identical cases showed the ABO-
identical survival rates were superior to those
in the ABO-compatible/non-identical group.
21
In  conclusion,  today  LT  is  a  treatment  of
choice for children with end-stage liver failure
due to irreversible liver damage caused by a
vast majority of pediatric diseases  which could
not  be  managed  in  the  past.  Cooperation
among a team of experts (hepatologists, trans-
plant  surgeons,  psychiatrists,  nurses,  social
workers) with the patient’s family is of out-
standing importance for a successful manage-
ment of the liver disease. Future approaches
such as the use of allo-grafts or hepatocytes, or
even blastocytes, may reduce the number of
children  who  currently  require  liver  grafts
from compatible donors.
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